HOWL Company Profile and Key Details

Q: Who are the executives of HOWL?

Dr. Reid Leonard Ph.D.Chief Operating OfficerDr. Daniel J. Hicklin Ph.D.Founder, Chief Executive Officer, Pres, Sec. & DirectorDr. Cynthia Seidel-Dugan Ph.D.Chief Scientific OfficerDr. Randi Isaacs M.D.Chief Medical OfficerMr. Timothy W. Trost CPAChief Financial Officer, Treasurer & Assistant Sec.Dr. Chulani Karunatilake Ph.D.Chief Technology OfficerMs. Ellen A. Lubman M.B.A.Chief Bus. Officer

NASDAQ : HOWL

Werewolf Therapeutics

$0.36

0.049+15.91%

Open: 2:54 PM

61.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Werewolf Therapeutics, Inc. (HOWL) stock surged +15.91%, trading at $0.36 on NASDAQ, up from the previous close of $0.31. The stock opened at $0.31, fluctuating between $0.30 and $0.36 in the recent session.

Stock Snapshot

0.308

Prev. Close

17.35M

Market Cap

0.3038

Day Low

-0.29

P/E Ratio

-1.24

EPS (TTM)

-0.91

Cash Flow per Share

0.31

Open

48.6M

Number of Shares

0.36

Day High

64.75%

Free Float in %

3.05

Book Value

910.32K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 29, 2026	0.33	0.34	0.27	0.31	2.38M
Jun 26, 2026	0.33	0.36	0.31	0.32	688.65K
Jun 25, 2026	0.38	0.38	0.33	0.33	643.28K
Jun 24, 2026	0.36	0.38	0.36	0.37	813.93K
Jun 23, 2026	0.37	0.38	0.36	0.36	515.61K
Jun 22, 2026	0.35	0.38	0.35	0.37	646.91K
Jun 18, 2026	0.36	0.38	0.34	0.35	1.58M
Jun 17, 2026	0.35	0.41	0.34	0.34	2.03M
Jun 16, 2026	0.39	0.40	0.36	0.36	580.23K
Jun 15, 2026	0.40	0.40	0.38	0.39	350.84K
Jun 12, 2026	0.39	0.42	0.38	0.38	425.4K
Jun 11, 2026	0.37	0.40	0.36	0.39	805.39K
Jun 10, 2026	0.36	0.38	0.36	0.37	169.73K
Jun 09, 2026	0.37	0.39	0.36	0.37	1.13M
Jun 08, 2026	0.39	0.42	0.37	0.38	690.62K
Jun 05, 2026	0.45	0.45	0.39	0.39	579.74K
Jun 04, 2026	0.43	0.45	0.43	0.43	209.76K
Jun 03, 2026	0.44	0.44	0.42	0.42	372.38K
Jun 01, 2026	0.46	0.50	0.45	0.47	429.65K
May 29, 2026	0.45	0.47	0.44	0.45	278.86K

Contact Details

Watertown, MA 02138

United States

https://werewolftx.com 617 952 0555

About Company

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

Stock Peers

ARGX

25.28+2.85%

argenx SE$912.46 REGN

-1.09-0.17%

Regeneron Pharmaceuticals, Inc.$631.81 UTHR

2.26+0.42%

United Therapeutics Corporation$544.92 MDGL

14.63+2.85%

Madrigal Pharmaceuticals, Inc.$527.28 VRTX

8.31+1.69%

Vertex Pharmaceuticals Incorporated$499.65 KRYS

5.9+1.58%

Krystal Biotech, Inc.$378.15 PRAX

22.77+6.95%

Praxis Precision Medicines, Inc.$350.56 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

10.45+3.44%

Ligand Pharmaceuticals Incorporated$314.04 ALNY

2.15+0.74%

Alnylam Pharmaceuticals, Inc.$293.52

Company Overview

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) closed at $0.36 USD, gaining $0.05 (15.91%) from the previous close of $0.31. The stock is currently mid-range between its 52-week high and low $0.27 and $2.38. With a market capitalization of about $17.35 million, Werewolf Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 583.53 thousand shares, trading with heavier-than-usual volume. Headquartered in Watertown, MA, Werewolf Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel J. Hicklin, the company employs approximately 46 people and listed since April 30, 2021. Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer.

Technical Performance

HOWL has shown weak momentum, losing -1.78% over the past week and -64.72% over the past quarter, though year-to-date performance is down -10.91%. Short-term trend indicators are bullishly aligned (SMA20 -4.72%, SMA50 -5.57%, SMA200 -45.18%). The stock’s 14-day RSI is 44.44 (neutral), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.45% below its high and over 19.2% above its low. Average 10-day trading volume of 947.97 thousand shares is significantly above the 3-month average of 602.24 thousand, indicating heightened recent market interest.

Valuation Metrics

Werewolf Therapeutics, Inc. trades at a P/E ratio of -0.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.23 suggesting the stock is closer to book value. The P/FCF stands at -0.29, also above market averages.

Dividend & Fair Value

Werewolf Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.04. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Werewolf Therapeutics, Inc. generated EPS of -$1.62 over the past year. Five-year average earnings growth is -20.76%. Wall Street analysts project EPS growth of -2.89% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$11.33. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $3.00. The high target offers 3125.81% upside. The low target suggests 867.74% downside. The mean target is $7.00. This offers 2158.06% upside. Werewolf Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -12.5%. The prior quarter beat by -41.18%. Over the last six quarters, Apple has recorded several small beats. These include 6.98% in March 11, 2025.

Shareholding & Insider Activity

Werewolf Therapeutics, Inc. has 45.73 million shares outstanding. The public float is 29.61 million shares, elevated short interest at 3.02% of float. This equals 982.02 thousand shares. The short ratio is 4.09 days. Institutional investors hold 31.94% of the float. Insiders own 5.61%. GADICKE ANSBERT holds 4.78 million shares, MPM BioVentures 2014, L.P. has 4.78 million shares and Flynn James E has 2.55 million shares. Over the past six months, insider transactions show net selling. They sold 2.55 million shares across 53 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Werewolf Therapeutics generated $19.94M in revenue, or $0.56 per share. Gross margin was 91.15%, operating margin -203.09%, and net profit margin -187.37%. Returns are negative, with ROA at -21.37% and ROE at -33.55%.
On valuation metrics, Werewolf Therapeutics trades at a P/E of -0.26, P/S of 0.00 and P/B of 1.23. The current ratio is 1.27 and quick ratio is 1.27. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1620.25 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 3.09, supported by a cash flow-to-debt ratio of -1.38.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Werewolf Therapeutics posted revenue of $19.94M, down slightly from $16.40M in the prior quarter. Gross profit was $18.18M (margin 91.15%). Operating income was - $40.50M (margin -203.1%). Net income was- $37.37M (EPS - $1.05).
The company ended the quarter with $134.34M in cash and short-term investments, a total debt of $51.92M, and net debt of - $82.42M. Total assets were $174.83M, with equity of $111.37M. Financials further reflected weakness, with operating cash flow of - $32.61M, free cash flow of - $33.38M, and capital expenditures of - $769.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Werewolf Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.58%, with price expected at $0.26 by July 13, 2026, within a range of $0.22 to $0.30 3-Month Outlook: Projected fall of -74.03%, reaching $0.08 by September 25, 2026, with a range of $0.04 to $0.12. 1-Year Outlook: Projected loss of -70.78%, with price at $0.09 by June 29, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares are down -10.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Werewolf Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.20, suggesting 3861.04% upside. Our AI forecast model points to short-term weakness (-15.58% over two weeks), a medium-term fall (-74.03% over three months), and a longer-term loss (-70.78% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Werewolf Therapeutics, Inc. (HOWL) stock price?

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) stock price is $0.36 in the last trading session. During the trading session, HOWL stock reached the peak price of $0.36 while $0.30 was the lowest point it dropped to. The percentage change in HOWL stock occurred in the recent session was 15.91% while the dollar amount for the price change in HOWL stock was $0.05.

HOWL's industry and sector of operation?

The NASDAQ listed HOWL is part of Biotechnology industry that operates in the broader Healthcare sector. Werewolf Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HOWL?

Dr. Reid Leonard Ph.D.
Chief Operating Officer
Dr. Daniel J. Hicklin Ph.D.
Founder, Chief Executive Officer, Pres, Sec. & Director
Dr. Cynthia Seidel-Dugan Ph.D.
Chief Scientific Officer
Dr. Randi Isaacs M.D.
Chief Medical Officer
Mr. Timothy W. Trost CPA
Chief Financial Officer, Treasurer & Assistant Sec.
Dr. Chulani Karunatilake Ph.D.
Chief Technology Officer
Ms. Ellen A. Lubman M.B.A.
Chief Bus. Officer

How HOWL did perform over past 52-week?

HOWL's closing price is 14.07% higher than its 52-week low of $0.27 where as its distance from 52-week high of $2.38 is -87.06%.

How many employees does HOWL have?

Number of HOWL employees currently stands at 46.

Link for HOWL official website?

Official Website of HOWL is: https://werewolftx.com

How do I contact HOWL?

HOWL could be contacted at phone 617 952 0555 and can also be accessed through its website. HOWL operates from 1030 Massachusetts Avenue, Watertown, MA 02138, United States.

How many shares of HOWL are traded daily?

HOWL stock volume for the day was 910.32K shares. The average number of HOWL shares traded daily for last 3 months was 583.53K.

What is the market cap of HOWL currently?

The market value of HOWL currently stands at $17.35M with its latest stock price at $0.36 and 48.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	46
Beta	0.27
Sales or Revenue	$19.94M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

HOWL Company Profile and Key Details

Werewolf Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook